{"type":"trials","record":{"id":42199,"source_id":"clinicaltrials-gov","external_id":"NCT05672979","title":"Prospective triAl of Modified Treat-and-extend Regimens With BroLucizumab in pachychOroid Neovasculopathy","brief_summary":"PNV is a recently described clinical entity; therefore, studies about treatment efficacy and safety are few, with limited follow-up and a small number of participants. Treatment is based on intravitreal anti-VEGF injections, similar to neovascular AMD. According to reported results however, efficacy seems different in fluid reabsorption among anti-VEGF agents. A newly developed anti-VEGF molecule for the treatment of neovascular AMD, brolucizumab, has been shown in clinical studies to have longer durability and improved visual outcomes using a q12-week regimen, thus having the potential to reduce treatment burden and serve as an important therapeutic tool in the management of neovascular AMD. Nevertheless, there have been no reports specifically focusing on the efficacy of brolucizumab in the treatment of PNV. The purpose of this study is to evaluate the efficacy and safety profile of the modified treat-and-extend regimen to 64 weeks by intravitreal brolucizumab injection in eyes with treatment-naive pachychoroid neovasculopathy (PNV) patients.","overall_status":"Unknown","phases":["PHASE3"],"study_type":"INTERVENTIONAL","sponsor":"Yeungnam University College of Medicine","enrollment":36,"countries":[],"start_date":"2023-01-01","completion_date":"2024-12-31","last_update_date":"2023-01-05","source_url":"https://clinicaltrials.gov/study/NCT05672979","editorial_summary":"A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"PABLO","age_range":"19 Years","comparator":null,"organization":"Yeungnam University College of Medicine","interventions":["Brolucizumab Injection [Beovu]"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Mean change from baseline in best corrected visual acuity — Week 32","Distribution of the last interval — up to Week 32 and Week 64","Distribution of the maximal interval — Week 64","Time from the last loading injection to the first visit with no disease activity — Week 64","Proportion of patients with no disease activity — Week 12","Proportion of patients with complete fluid absorption — Week 12, Week 16"],"design_description":"NA · SINGLE GROUP · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Age-Related Macular Degeneration","Pachychoroid Neovasculopathy","Brolucizumab Injection [Beovu]"],"relevance_confidence":60,"source_quality_score":100,"freshness_score":50,"publication_state":"published","match_explanation":"Source terminology contains: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct05672979","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2023-01-01 to 2024-12-31","comparator":null,"confidence":"structured-source","population":"ALL · 19 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.934Z","intervention":["Brolucizumab Injection [Beovu]"],"participants":36,"study_design":"NA · SINGLE GROUP · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE3","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Mean change from baseline in best corrected visual acuity — Week 32","Distribution of the last interval — up to Week 32 and Week 64","Distribution of the maximal interval — Week 64","Time from the last loading injection to the first visit with no disease activity — Week 64","Proportion of patients with no disease activity — Week 12","Proportion of patients with complete fluid absorption — Week 12, Week 16"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Source terminology contains: age-related macular degeneration.","Source terminology supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["controlled terminology","controlled context","study type"],"relevance_score":60,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42199","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}